Yes...Keyman188 always sorhae...

Hope you don't so much jealous...

wkwkwk...kekeke...

(Forgot to tell you this so-hai street beggar, Keyman188 already trapped a lot of different counters...DLady, Ajinomoto, HLFG, HLCap, Tenaga, Genting, Axiata, Padini, Ambank, Mynews, IJM, SPSetia, UEM Edgenta, Kerjaya, Parkson...etc...etc...)...


Hopefully this so-hai street beggar not always jealous so much Keyman188....


Kesian...kesian...







Posted by gemfinder > Mar 23, 2021 7:33 PM | Report Abuse

Sorhae keyman kena trap gao gao

Lol...manage to top up today @0.940...

Cheers......

Aiyo...Keyman188 already told you this morning immediate support @ 5.12 / 5.13....

Can not be this level lahh...

This counter not kacang putih counter lahhh....





Posted by Stocksafeplayer > Mar 23, 2021 4:26 PM | Report Abuse

Wa....Still not reach 5.05 yet?

Aiyo...you also betting UMW...

Keyman188 sold all last year around the range 2.60 ~ 2.65 but not managed to collect back...

Haizzz....Is Keyman188 big big mistake...





Posted by DestinyL > Mar 23, 2021 4:22 PM | Report Abuse

Glad I took profit on my short term positions in Padini and UMW
Hopefully can buyback soon

Lol...just wake up for breakfast...

@Stocksafeplayer...aiyoo....really T40 rich investor...

Salute....

Aiyo...suddenly the rest so quiet liao...

Very strange....

Yes...Keyman188 always worry unable to catch the "Mr.Right"....haizzz....

1) Ambank

2) UMW

3) ABMB

4) HLCap

5) Muhibah

All waiting shortlisted list....





Posted by Stocksafeplayer > Mar 23, 2021 3:54 PM | Report Abuse

Are you worried Keyman188?

Adui...Long term investors shall be happy....not to be worry...


wkwkwk...kekeke...


Give you chance to collect mahhh....


But...Keyman188 always prefer diversification....


Cheers.......

This morning Keyman188 already mentioned earlier...

Seem like a lot of members thought Keyman188 "blow water never wipe mouth"....


wkwkwk...kekeke...

Aiya...just +-2pt lorrr....

Next immediate support level fall @ 4.88


Cheers............




Posted by Keyman188 > Mar 23, 2021 9:52 AM | Report Abuse X

Today Genting very high possibility to test immediate support level @ 5.12 / 5.13...


Cheers..........

Keyman188 will hold until can see US$3.50...

wkwkwk...kekeke...hehehe...

A lot members felt Keyman188 is madness...

Do you know KLCI can hit 2300 ~ 2400 for the next 6 ~ 7 years !!!...




Posted by Sharefisher > Mar 23, 2021 10:05 AM | Report Abuse

I will hold until next year. And my average price is well below 4. Pls don't 以小人之心度君子之腹！

Aiyo...Keyman188 looking for "nasi lemak + kopi O" meal...

market nosediving to -10pt ++...

Cheers.............

Today Genting very high possibility to test immediate support level @ 5.12 / 5.13...


Cheers..........

Really laugh die Keyman188 lorrr....


Old man always say...


"瘦田无人耕 耕开有人争"


"There is no one to plow the slender field, when the field over plowing people start to dispute farming"


wkwkwk...kekeke...hehehe...

Laugh die Keyman188...

Keyman188 will not blame for those "coward street beggar" never study or understand the accounting academic...

wkwkwk...kekeke...

Keyman188 very nervous & naive...

Keyman188 feel very scary behind the Master...

Keyman188 no so concern uncle...

Do you know who is the pilot of this co. !!!...

Aiyo...you think Keyman188 just born yesterday mehhh...

We all still waiting concrete decisions...not just Hollywood & Bollywood shows...

Of course whatever complaint definitely open file lahhh...

You know what is UMA query???...

Also same practice open file investigate lahhh...

wkwkwk...kekeke...hehehe




Posted by yingzhe17 > Mar 22, 2021 7:31 PM | Report Abuse 

Keyman188, you not read the news ?
The has accepted and opened a file to investigate.

Can Keyman188 join the party???...

Did you realise China biz contributions gradually increased from 3 years ago 65% ++ to 79%++ (based on the latest quarterly report review)...

Aiyo...always Genting only mehhh...

For those long term position like Keyman188 already put at the fridge for upcoming tp US$3.50 lorrr + yearly passive income dividend lorrr...

Keyman188 aiming for another "Nasi lemak + Kopi O" pocket money...SCIB...Parkson...

This few days fishing...


wkwkwk...kekeke...hehehe...

Upcoming day Keyman188 still continue playing around this Supermax since the rest long term position already put at the fridge for future fruition harvest...

wkwkwk...kekeke...

Nowadays glove sector no need so greedy liao..

Buy sell buy sell....

So just earn some nasi lemak + Kopi O lorrr....

Haa...Keyman188 bought Supermax last week @ 4.21...

Today short term profit @ 4.36....


wkwkwk...kekeke...






Posted by Stocksafeplayer > Mar 22, 2021 4:36 PM | Report Abuse

Gloves RED RED!!
Better RUN Now!!!

AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

(PUBLISHED MON, MAR 22 20213:10 AM EDTUPDATED MON, MAR 22 20214:09 AM EDT)

~ The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

~ It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

~ AstraZeneca said an independent data safety monitoring board identified no safety concerns related to the shot.

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization.

The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

By comparison, Moderna’s vaccine has been found to be more than 94% effective in preventing Covid, and Pfizer-BioNTech’s vaccine was found to be 95% effective.

AstraZeneca said it would continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drugs Administration for emergency use authorization in the coming weeks.

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people. Health experts sharply criticized the move, citing a lack of data, while analysts expressed concern about the impact on vaccine uptake as the virus continues to spread.

Germany, France, Italy and Spain are among those to have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is both safe and effective.

AstraZeneca said in a release Monday that an independent board identified no safety concerns related to the shot. They also conducted a specific review of blood clots as well as cerebral venous sinus thrombosis (CVST), an extremely rare blood clot in the brain, with the help of an independent neurologist.

The data safety monitoring board “found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial.”

Cont...


## https://www.cnbc.com/2021/03/22/astrazeneca-coronavirus-vaccine-79percent-effective-in-us-trial.html


^^^ Another high effective vaccine roll out globally...

AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

(PUBLISHED MON, MAR 22 20213:10 AM EDTUPDATED MON, MAR 22 20214:09 AM EDT)

~ The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

~ It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

~ AstraZeneca said an independent data safety monitoring board identified no safety concerns related to the shot.

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization.

The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

By comparison, Moderna’s vaccine has been found to be more than 94% effective in preventing Covid, and Pfizer-BioNTech’s vaccine was found to be 95% effective.

AstraZeneca said it would continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drugs Administration for emergency use authorization in the coming weeks.

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people. Health experts sharply criticized the move, citing a lack of data, while analysts expressed concern about the impact on vaccine uptake as the virus continues to spread.

Germany, France, Italy and Spain are among those to have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is both safe and effective.

AstraZeneca said in a release Monday that an independent board identified no safety concerns related to the shot. They also conducted a specific review of blood clots as well as cerebral venous sinus thrombosis (CVST), an extremely rare blood clot in the brain, with the help of an independent neurologist.

The data safety monitoring board “found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial.”

‘Much-needed’ additional vaccination option

Ann Falsey, professor of medicine at University of Rochester School of Medicine, U.S., and co-lead principal investigator for the trial, said: “This analysis validates the AstraZeneca COVID-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus.”

The pharmaceutical giant said the shot was well tolerated and its effectiveness was found to be consistent across ethnicity and age. Notably, the Oxford-AstraZeneca shot was 80% effective in preventing Covid in participants aged 65 years and above.

“These results add to the growing body of evidence that shows this vaccine is well tolerated and highly effective against all severities of COVID-19 and across all age groups,” Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca, said in a statement.

“We are confident this vaccine can play an important role in protecting millions of people worldwide against this lethal virus,” Pangalos said.

Among the participants in the interim analysis, roughly 20% were 65 years of age and above, while approximately 60% had comorbidities associated with an increased risk for progression of severe Covid, such as diabetes or cardiac disease.


## https://www.cnbc.com/2021/03/22/astrazeneca-coronavirus-vaccine-79percent-effective-in-us-trial.html


^^^ Another high effective vaccine roll out globally...

AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

(PUBLISHED MON, MAR 22 20213:10 AM EDTUPDATED MON, MAR 22 20214:09 AM EDT)

~ The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

~ It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

~ AstraZeneca said an independent data safety monitoring board identified no safety concerns related to the shot.

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization.

The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

By comparison, Moderna’s vaccine has been found to be more than 94% effective in preventing Covid, and Pfizer-BioNTech’s vaccine was found to be 95% effective.

AstraZeneca said it would continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drugs Administration for emergency use authorization in the coming weeks.

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people. Health experts sharply criticized the move, citing a lack of data, while analysts expressed concern about the impact on vaccine uptake as the virus continues to spread.

Germany, France, Italy and Spain are among those to have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is both safe and effective.

AstraZeneca said in a release Monday that an independent board identified no safety concerns related to the shot. They also conducted a specific review of blood clots as well as cerebral venous sinus thrombosis (CVST), an extremely rare blood clot in the brain, with the help of an independent neurologist.

The data safety monitoring board “found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial.”

‘Much-needed’ additional vaccination option

Ann Falsey, professor of medicine at University of Rochester School of Medicine, U.S., and co-lead principal investigator for the trial, said: “This analysis validates the AstraZeneca COVID-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus.”

The pharmaceutical giant said the shot was well tolerated and its effectiveness was found to be consistent across ethnicity and age. Notably, the Oxford-AstraZeneca shot was 80% effective in preventing Covid in participants aged 65 years and above.

“These results add to the growing body of evidence that shows this vaccine is well tolerated and highly effective against all severities of COVID-19 and across all age groups,” Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca, said in a statement.

“We are confident this vaccine can play an important role in protecting millions of people worldwide against this lethal virus,” Pangalos said.

Among the participants in the interim analysis, roughly 20% were 65 years of age and above, while approximately 60% had comorbidities associated with an increased risk for progression of severe Covid, such as diabetes or cardiac disease.


## https://www.cnbc.com/2021/03/22/astrazeneca-coronavirus-vaccine-79percent-effective-in-us-trial.html

AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

(PUBLISHED MON, MAR 22 20213:10 AM EDTUPDATED MON, MAR 22 20214:09 AM EDT)

~ The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

~ It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

~ AstraZeneca said an independent data safety monitoring board identified no safety concerns related to the shot.

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization.

The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

By comparison, Moderna’s vaccine has been found to be more than 94% effective in preventing Covid, and Pfizer-BioNTech’s vaccine was found to be 95% effective.

AstraZeneca said it would continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drugs Administration for emergency use authorization in the coming weeks.

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people. Health experts sharply criticized the move, citing a lack of data, while analysts expressed concern about the impact on vaccine uptake as the virus continues to spread.

Germany, France, Italy and Spain are among those to have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is both safe and effective.

AstraZeneca said in a release Monday that an independent board identified no safety concerns related to the shot. They also conducted a specific review of blood clots as well as cerebral venous sinus thrombosis (CVST), an extremely rare blood clot in the brain, with the help of an independent neurologist.

The data safety monitoring board “found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial.”

‘Much-needed’ additional vaccination option

Ann Falsey, professor of medicine at University of Rochester School of Medicine, U.S., and co-lead principal investigator for the trial, said: “This analysis validates the AstraZeneca COVID-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus.”

The pharmaceutical giant said the shot was well tolerated and its effectiveness was found to be consistent across ethnicity and age. Notably, the Oxford-AstraZeneca shot was 80% effective in preventing Covid in participants aged 65 years and above.

“These results add to the growing body of evidence that shows this vaccine is well tolerated and highly effective against all severities of COVID-19 and across all age groups,” Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca, said in a statement.

“We are confident this vaccine can play an important role in protecting millions of people worldwide against this lethal virus,” Pangalos said.

Among the participants in the interim analysis, roughly 20% were 65 years of age and above, while approximately 60% had comorbidities associated with an increased risk for progression of severe Covid, such as diabetes or cardiac disease.


## https://www.cnbc.com/2021/03/22/astrazeneca-coronavirus-vaccine-79percent-effective-in-us-trial.html

Another high effective vaccine roll out globally...

AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

(PUBLISHED MON, MAR 22 20213:10 AM EDTUPDATED MON, MAR 22 20214:09 AM EDT)

~ The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

~ It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

~ AstraZeneca said an independent data safety monitoring board identified no safety concerns related to the shot.

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization.

The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

By comparison, Moderna’s vaccine has been found to be more than 94% effective in preventing Covid, and Pfizer-BioNTech’s vaccine was found to be 95% effective.

AstraZeneca said it would continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drugs Administration for emergency use authorization in the coming weeks.

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people. Health experts sharply criticized the move, citing a lack of data, while analysts expressed concern about the impact on vaccine uptake as the virus continues to spread.

Germany, France, Italy and Spain are among those to have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is both safe and effective.

AstraZeneca said in a release Monday that an independent board identified no safety concerns related to the shot. They also conducted a specific review of blood clots as well as cerebral venous sinus thrombosis (CVST), an extremely rare blood clot in the brain, with the help of an independent neurologist.

The data safety monitoring board “found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial.”

‘Much-needed’ additional vaccination option

Ann Falsey, professor of medicine at University of Rochester School of Medicine, U.S., and co-lead principal investigator for the trial, said: “This analysis validates the AstraZeneca COVID-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus.”

The pharmaceutical giant said the shot was well tolerated and its effectiveness was found to be consistent across ethnicity and age. Notably, the Oxford-AstraZeneca shot was 80% effective in preventing Covid in participants aged 65 years and above.

“These results add to the growing body of evidence that shows this vaccine is well tolerated and highly effective against all severities of COVID-19 and across all age groups,” Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca, said in a statement.

“We are confident this vaccine can play an important role in protecting millions of people worldwide against this lethal virus,” Pangalos said.

Among the participants in the interim analysis, roughly 20% were 65 years of age and above, while approximately 60% had comorbidities associated with an increased risk for progression of severe Covid, such as diabetes or cardiac disease.


## https://www.cnbc.com/2021/03/22/astrazeneca-coronavirus-vaccine-79percent-effective-in-us-trial.html

Another high effective vaccine roll out globally...

AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

(PUBLISHED MON, MAR 22 20213:10 AM EDTUPDATED MON, MAR 22 20214:09 AM EDT)

~ The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

~ It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

~ AstraZeneca said an independent data safety monitoring board identified no safety concerns related to the shot.

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization.

The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

By comparison, Moderna’s vaccine has been found to be more than 94% effective in preventing Covid, and Pfizer-BioNTech’s vaccine was found to be 95% effective.

AstraZeneca said it would continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drugs Administration for emergency use authorization in the coming weeks.

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people. Health experts sharply criticized the move, citing a lack of data, while analysts expressed concern about the impact on vaccine uptake as the virus continues to spread.

Germany, France, Italy and Spain are among those to have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is both safe and effective.

AstraZeneca said in a release Monday that an independent board identified no safety concerns related to the shot. They also conducted a specific review of blood clots as well as cerebral venous sinus thrombosis (CVST), an extremely rare blood clot in the brain, with the help of an independent neurologist.

The data safety monitoring board “found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial.”

‘Much-needed’ additional vaccination option

Ann Falsey, professor of medicine at University of Rochester School of Medicine, U.S., and co-lead principal investigator for the trial, said: “This analysis validates the AstraZeneca COVID-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus.”

The pharmaceutical giant said the shot was well tolerated and its effectiveness was found to be consistent across ethnicity and age. Notably, the Oxford-AstraZeneca shot was 80% effective in preventing Covid in participants aged 65 years and above.

“These results add to the growing body of evidence that shows this vaccine is well tolerated and highly effective against all severities of COVID-19 and across all age groups,” Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca, said in a statement.

“We are confident this vaccine can play an important role in protecting millions of people worldwide against this lethal virus,” Pangalos said.

Among the participants in the interim analysis, roughly 20% were 65 years of age and above, while approximately 60% had comorbidities associated with an increased risk for progression of severe Covid, such as diabetes or cardiac disease.


## https://www.cnbc.com/2021/03/22/astrazeneca-coronavirus-vaccine-79percent-effective-in-us-trial.html

Another high effective vaccine roll out...

AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

(PUBLISHED MON, MAR 22 20213:10 AM EDTUPDATED MON, MAR 22 20214:09 AM EDT)

~ The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

~ It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

~ AstraZeneca said an independent data safety monitoring board identified no safety concerns related to the shot.

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization.

The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

By comparison, Moderna’s vaccine has been found to be more than 94% effective in preventing Covid, and Pfizer-BioNTech’s vaccine was found to be 95% effective.

AstraZeneca said it would continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drugs Administration for emergency use authorization in the coming weeks.

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people. Health experts sharply criticized the move, citing a lack of data, while analysts expressed concern about the impact on vaccine uptake as the virus continues to spread.

Germany, France, Italy and Spain are among those to have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is both safe and effective.

AstraZeneca said in a release Monday that an independent board identified no safety concerns related to the shot. They also conducted a specific review of blood clots as well as cerebral venous sinus thrombosis (CVST), an extremely rare blood clot in the brain, with the help of an independent neurologist.

The data safety monitoring board “found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial.”

‘Much-needed’ additional vaccination option

Ann Falsey, professor of medicine at University of Rochester School of Medicine, U.S., and co-lead principal investigator for the trial, said: “This analysis validates the AstraZeneca COVID-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus.”

The pharmaceutical giant said the shot was well tolerated and its effectiveness was found to be consistent across ethnicity and age. Notably, the Oxford-AstraZeneca shot was 80% effective in preventing Covid in participants aged 65 years and above.

“These results add to the growing body of evidence that shows this vaccine is well tolerated and highly effective against all severities of COVID-19 and across all age groups,” Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca, said in a statement.

“We are confident this vaccine can play an important role in protecting millions of people worldwide against this lethal virus,” Pangalos said.

Among the participants in the interim analysis, roughly 20% were 65 years of age and above, while approximately 60% had comorbidities associated with an increased risk for progression of severe Covid, such as diabetes or cardiac disease.


## https://www.cnbc.com/2021/03/22/astrazeneca-coronavirus-vaccine-79percent-effective-in-us-trial.html

Another high effective vaccine roll out...

AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

(PUBLISHED MON, MAR 22 20213:10 AM EDTUPDATED MON, MAR 22 20214:09 AM EDT)

~ The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

~ It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

~ AstraZeneca said an independent data safety monitoring board identified no safety concerns related to the shot.

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization.

The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

By comparison, Moderna’s vaccine has been found to be more than 94% effective in preventing Covid, and Pfizer-BioNTech’s vaccine was found to be 95% effective.

AstraZeneca said it would continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drugs Administration for emergency use authorization in the coming weeks.

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people. Health experts sharply criticized the move, citing a lack of data, while analysts expressed concern about the impact on vaccine uptake as the virus continues to spread.

Germany, France, Italy and Spain are among those to have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is both safe and effective.

AstraZeneca said in a release Monday that an independent board identified no safety concerns related to the shot. They also conducted a specific review of blood clots as well as cerebral venous sinus thrombosis (CVST), an extremely rare blood clot in the brain, with the help of an independent neurologist.

The data safety monitoring board “found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial.”

‘Much-needed’ additional vaccination option

Ann Falsey, professor of medicine at University of Rochester School of Medicine, U.S., and co-lead principal investigator for the trial, said: “This analysis validates the AstraZeneca COVID-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus.”

The pharmaceutical giant said the shot was well tolerated and its effectiveness was found to be consistent across ethnicity and age. Notably, the Oxford-AstraZeneca shot was 80% effective in preventing Covid in participants aged 65 years and above.

“These results add to the growing body of evidence that shows this vaccine is well tolerated and highly effective against all severities of COVID-19 and across all age groups,” Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca, said in a statement.

“We are confident this vaccine can play an important role in protecting millions of people worldwide against this lethal virus,” Pangalos said.

Among the participants in the interim analysis, roughly 20% were 65 years of age and above, while approximately 60% had comorbidities associated with an increased risk for progression of severe Covid, such as diabetes or cardiac disease.


## https://www.cnbc.com/2021/03/22/astrazeneca-coronavirus-vaccine-79percent-effective-in-us-trial.html

Another high effective vaccine....

AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

(PUBLISHED MON, MAR 22 20213:10 AM EDTUPDATED MON, MAR 22 20214:09 AM EDT)

~ The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

~ It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

~ AstraZeneca said an independent data safety monitoring board identified no safety concerns related to the shot.

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization.

The safety and efficacy analysis of the vaccine, published Monday, was based on 32,449 participants from a Phase 3 trial.

By comparison, Moderna’s vaccine has been found to be more than 94% effective in preventing Covid, and Pfizer-BioNTech’s vaccine was found to be 95% effective.

AstraZeneca said it would continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drugs Administration for emergency use authorization in the coming weeks.

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people. Health experts sharply criticized the move, citing a lack of data, while analysts expressed concern about the impact on vaccine uptake as the virus continues to spread.

Germany, France, Italy and Spain are among those to have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is both safe and effective.

AstraZeneca said in a release Monday that an independent board identified no safety concerns related to the shot. They also conducted a specific review of blood clots as well as cerebral venous sinus thrombosis (CVST), an extremely rare blood clot in the brain, with the help of an independent neurologist.

The data safety monitoring board “found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial.”

‘Much-needed’ additional vaccination option

Ann Falsey, professor of medicine at University of Rochester School of Medicine, U.S., and co-lead principal investigator for the trial, said: “This analysis validates the AstraZeneca COVID-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus.”

The pharmaceutical giant said the shot was well tolerated and its effectiveness was found to be consistent across ethnicity and age. Notably, the Oxford-AstraZeneca shot was 80% effective in preventing Covid in participants aged 65 years and above.

“These results add to the growing body of evidence that shows this vaccine is well tolerated and highly effective against all severities of COVID-19 and across all age groups,” Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca, said in a statement.

“We are confident this vaccine can play an important role in protecting millions of people worldwide against this lethal virus,” Pangalos said.

Among the participants in the interim analysis, roughly 20% were 65 years of age and above, while approximately 60% had comorbidities associated with an increased risk for progression of severe Covid, such as diabetes or cardiac disease.


## https://www.cnbc.com/2021/03/22/astrazeneca-coronavirus-vaccine-79percent-effective-in-us-trial.html

Blackstone foresee huge business growth that's why is the right time to tap in casino business....


Cheers....




Posted by Keyman188 > Mar 22, 2021 11:02 AM | Report Abuse X

Blackstone makes $6.2bn bid for Australian casino operator Crown

About Blackstone

Our $619 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis.

Blackstone makes $6.2bn bid for Australian casino operator Crown

US private equity firm Blackstone Group has made an A$8bn (US$6.2bn) bid to buy Crown Resorts, the under-pressure gaming business backed by Australian billionaire James Packer.

The unsolicited offer by Blackstone followed a ruling by Australian regulators last month that Crown was not fit to operate a new A$2.2bn casino resort in Sydney because of concerns about money laundering and poor corporate governance.

Crown said on Monday that the buyout offer represented A$11.85 a share, or about a 19 per cent premium to the gaming group’s average stock price since it published its first-half financial results over a month ago.

Crown added that the bid was subject to due diligence, approval by Blackstone’s investment committees and a decision by Australian regulators that the US private equity group was a suitable entity to operate its portfolio of casinos in Sydney, Melbourne and Perth.

“The Crown board has not yet formed a view on the merits of the proposal. It will now commence a process to assess the proposal, having regard to the value and terms of the proposal and other considerations. It will also engage with relevant stakeholders including regulatory authorities,” said Crown in a statement to the Australian Securities Exchange.

Shares in Crown jumped 18 per cent to A$11.61 on Monday following the news.

If a deal can be agreed, it would mark a further push by Blackstone into the casino sector following its $4.25bn deal to acquire the Bellagio resort in Las Vegas from MGM Resorts International in October 2019.

Blackstone already owns 9.9 per cent of Crown and has been tipped as a potential acquirer of the company.

Packer, who owns 37 per cent of Crown and built the company into Australia’s biggest gaming group, will be pivotal to any agreement with Blackstone. However, analysts believed that there were signs he would be a willing seller because of the regulatory hurdles facing Crown and his own personal circumstances.

The billionaire resigned from Crown’s board of directors in 2018, citing mental health issues — a move that followed the arrest and conviction of 19 of the group’s employees in China. A recent report by a government-commissioned inquiry criticised Packer, saying his capacity to “remotely manoeuvre” operations must cease for the health of the company.

The report concluded that Crown was not fit to operate its flagship A$2.2bn casino in Sydney and that the company had unwittingly facilitated money laundering.

“The very serious problems of the infiltration of Crown subsidiaries’ accounts by organised criminals should send a shiver down the spine not only of any casino regulator but also the community generally,” said the report by Patricia Bergin, a former judge.

Crown accepted the resignations of five of its directors following the report. The company still faces two state government commissioned inquiries in Victoria and Western Australia in the coming months.

Kelly Amato, an analyst at Fitch Ratings, said a deal with Blackstone may help Crown address some of the issues highlighted by the report regarding Crown’s relationship with CPH, Packer’s private investment vehicle.

“Even though Crown has already terminated agreements with CPH and its representatives on Crown’s board have already resigned, we believe the removal of CPH as a shareholder will be viewed favourably by the regulators as it will provide a permanent break in the relationship,” she said.

## https://www.ft.com/content/061bd2f8-11cb-4d2f-ad40-6bcb40410977

@Trevor777...Thank you for your support Keyman188 prospective on the counter...

Keyman188 already highlighted so many time since Dec'20 until Jan'21...

Seem like a lot of newbies felt Keyman188 talk cock or "blow water never wipe mouth"...

You all had seen Jan'21 comments ???...

So what is the price range now ???

Is it almost matching with Keyman188 prediction???...

Keyman188 once again to highlight, if upcoming quarterly result unable to growth further, very high possibility anytime shall be neutralised between 1.80 ~ 2.00....

Please spend some time to review past 2 quarterly report...

Keyman188 still casualty to review this company but Keyman188 will not invest 1st either upcoming quarterly result can indicate further growth or until the share price to be neutralised...






Posted by Keyman188 > Jan 1, 2021 9:08 PM | Report Abuse

Keyman188 always like to repeat & repeat to remind market again...

Time to wake up switching to economy recovery stocks...

Smart money already gone & had switched to others....

Keyman188 foresee further downside risk towards 2.80 ~ 3.00......

If unable to support, further downside risk towards 2.55 ~ 2.65...

Don't be hero to fight current level......



Even though you all plan to keep it for long term...

But not at this point since overall this counter sentiment remained very very weak...

Don't burnt your hard earned money......

For more safety margin better be more patience until below 3.00 then decide again......

Fyi, for the past few years record range, 1.30 ~ 1.60.....

Only this year is different because of heading more speculation then shot up above 4.00......

----------------------------------------------------------------------------------------------------------

Posted by Keyman188 > Dec 15, 2020 2:20 PM | Report Abuse

Keyman188 wants to see if the share price drop back to the range 2.00 ~ 2.30 for the next 12 month...then ding dong ding dong this range another 2 /3 years....

wkwkwk...wkwkwk..kekeke...kekeke.....

Aiyo...behave like Saham Master....


wkwkwk...kekeke...

So how ???...

We all waiting show right now???...

Don't always "blow water never wipe mouth"...

Seem like you are part of the Hollywood or Bollywood actor now...


wkwkwk...kekeke...





Posted by yingzhe17 > Mar 16, 2021 8:11 PM | Report Abuse

Wrote to SC. Wait for reply

Laugh die Keyman188 lorrr....


Keyman188 holding Tenaga share average cost only 7.80++


Last year just collected 22 sen dividend & this year collect again 58 sen dividend...


The dividend yield become 10.2% liao.....


unbelievable....Fantastic........


If you are receiving more than 10% dividend yield annually, you think still want to dispose it !!!........


wkwkwk.......kekeke.......


Keep it for passive income lahhh..


^^^Hope sourgrape "coward street beggar" didn't jealous Keyman188 again...


wkwkwk...kekeke...

Laugh die Keyman188 lorrr....

Seem like another sourgrape "coward street beggar" miss the boat liao...

Kesian...kesian...

Keyman188 always learn from professional or experts...

应买价值股还是成长股？(冷眼)

“年均复合增长率”致富关键 (冷眼)

https://klse.i3investor.com/blogs/cold_eyed_step_by_step/2021-03-20-story-h1542898574.jsp

https://www.enanyang.my/财经新闻/应买价值股还是成长股？（上）冷眼

https://klse.i3investor.com/blogs/cold_eyed_step_by_step/2021-03-21-story-h1542901613.jsp

https://www.enanyang.my/名人专栏/“年均复合增长率”致富关键（下）冷眼


------------------------------------------------------------------------------------------------

Keyman188 very gladness to share with all members here...

Keyman188 has been using 12 months period of time (since last year Mar'20) managed to organize long term portfolio position what I learned from professional (冷眼先生)

Let using Genting share as an example...

Keyman188 holding cost average about 3.30++...

Keyman188 had received dividend received for the past 12 months (based on ex-date from Apr'20 ~ Mar'21)

12/03/21 - RM 0.085

10/09/20 - RM 0.065

29/06/20 - RM 0.06

Total dividend received = RM 0.210

Dividend yield = 6.26% per share

Furthermore, since Genting part of the recovery stock with strong fundamental & growing company....

Recent share price also gradually on the recovery road...

Capital appreciation of investment also part of the investment return...

Capital appreciation growth = +65% (based on 19/03/21 closing price of RM 5.53)

Why Keyman188 so keen to keep long term position instead of short term Profit !!!........

1) Genting Management never neve stop further expansion for the business growth (even though during virus pandemic, management also taken effectiveness & efficiency measures to sustain company keep running for growth)

2) Asset quality of company no doubt definitely very strong (based the company latest balance sheet)

3) Management still able to reward dividend for all shareholders even though very struggling for the global market (still constantly payout for the past 10 years - no need talk so long period to review)

4) Foresee dividend payout will be gradually increased for the next 10 years if the global economy & market recovery with company expansion on the perpetual growth

5) Cash pile reserve still on track (even though so much noise for bailout at different subsidiary)

6) No matter current ratio, quality of earnings ratio, NAV, cash pile position will further strengthen for upcoming season


------------------------------------------------------------------------------------------------

Beside Genting share under long term position, Keyman188 also managed to secure right company, such as :-

DLady, Ajinomoto, HLFG, HLCap, Axiata, Padini, SP Setia, IJM, Mynews, etc....

Depending how much stocks you can handle (average long term investors willing to handle 10 ~ 12 stocks, for those willing to take higher risk perhaps can handle 15 ~ 25 stocks)

Keyman188 more prefer diversification into different sectors & segmentations for more "balancing & alignment" approach on the "risk-weighted asset" management...


------------------------------------------------------------------------------------------------

Is it the right time to start your million dollar dream ???...

Is it the right time to start your long term position instead of short term profit ???....


** The final decision is on your heart now

Keyman188 always learn from professional or experts...

应买价值股还是成长股？(冷眼)

“年均复合增长率”致富关键 (冷眼)

https://klse.i3investor.com/blogs/cold_eyed_step_by_step/2021-03-20-story-h1542898574.jsp

https://www.enanyang.my/财经新闻/应买价值股还是成长股？（上）冷眼

https://klse.i3investor.com/blogs/cold_eyed_step_by_step/2021-03-21-story-h1542901613.jsp

https://www.enanyang.my/名人专栏/“年均复合增长率”致富关键（下）冷眼


------------------------------------------------------------------------------------------------

Keyman188 very gladness to share with all members here...

Keyman188 has been using 12 months period of time (since last year Mar'20) managed to organize long term portfolio position what I learned from professional (冷眼先生)

Let using Genting share as an example...

Keyman188 holding cost average about 3.30++...

Keyman188 had received dividend received for the past 12 months (based on ex-date from Apr'20 ~ Mar'21)

12/03/21 - RM 0.085

10/09/20 - RM 0.065

29/06/20 - RM 0.06

Total dividend received = RM 0.210

Dividend yield = 6.26% per share

Furthermore, since Genting part of the recovery stock with strong fundamental & growing company....

Recent share price also gradually on the recovery road...

Capital appreciation of investment also part of the investment return...

Capital appreciation growth = +65% (based on 19/03/21 closing price of RM 5.53)

Why Keyman188 so keen to keep long term position instead of short term Profit !!!........

1) Genting Management never neve stop further expansion for the business growth (even though during virus pandemic, management also taken effectiveness & efficiency measures to sustain company keep running for growth)

2) Asset quality of company no doubt definitely very strong (based the company latest balance sheet)

3) Management still able to reward dividend for all shareholders even though very struggling for the global market (still constantly payout for the past 10 years - no need talk so long period to review)

4) Foresee dividend payout will be gradually increased for the next 10 years if the global economy & market recovery with company expansion on the perpetual growth

5) Cash pile reserve still on track (even though so much noise for bailout at different subsidiary)

6) No matter current ratio, quality of earnings ratio, NAV, cash pile position will further strengthen for upcoming season


------------------------------------------------------------------------------------------------

Beside Genting share under long term position, Keyman188 also managed to secure right company, such as :-

DLady, Ajinomoto, HLFG, HLCap, Axiata, Padini, SP Setia, IJM, Mynews, etc....

Depending how much stocks you can handle (average long term investors willing to handle 10 ~ 12 stocks, for those willing to take higher risk perhaps can handle 15 ~ 25 stocks)

Keyman188 more prefer diversification into different sectors & segmentations for more "balancing & alignment" approach on the "risk-weighted asset" management...


------------------------------------------------------------------------------------------------

Is it the right time to start your million dollar dream ???...

Is it the right time to start your long term position instead of short term profit ???....


** The final decision is on your heart now

Keyman188 always learn from professional or experts...

应买价值股还是成长股？(冷眼)

“年均复合增长率”致富关键 (冷眼)

https://klse.i3investor.com/blogs/cold_eyed_step_by_step/2021-03-20-story-h1542898574.jsp

https://www.enanyang.my/财经新闻/应买价值股还是成长股？（上）冷眼

https://klse.i3investor.com/blogs/cold_eyed_step_by_step/2021-03-21-story-h1542901613.jsp

https://www.enanyang.my/名人专栏/“年均复合增长率”致富关键（下）冷眼


------------------------------------------------------------------------------------------------

Keyman188 very gladness to share with all members here...

Keyman188 has been using 12 months period of time (since last year Mar'20) managed to organize long term portfolio position what I learned from professional (冷眼先生)

Let using Genting share as an example...

Keyman188 holding cost average about 3.30++...

Keyman188 had received dividend received for the past 12 months (based on ex-date from Apr'20 ~ Mar'21)

12/03/21 - RM 0.085

10/09/20 - RM 0.065

29/06/20 - RM 0.06

Total dividend received = RM 0.210

Dividend yield = 6.26% per share

Furthermore, since Genting part of the recovery stock with strong fundamental & growing company....

Recent share price also gradually on the recovery road...

Capital appreciation of investment also part of the investment return...

Capital appreciation growth = +65% (based on 19/03/21 closing price of RM 5.53)

Why Keyman188 so keen to keep long term position instead of short term Profit !!!........

1) Genting Management never neve stop further expansion for the business growth (even though during virus pandemic, management also taken effectiveness & efficiency measures to sustain company keep running for growth)

2) Asset quality of company no doubt definitely very strong (based the company latest balance sheet)

3) Management still able to reward dividend for all shareholders even though very struggling for the global market (still constantly payout for the past 10 years - no need talk so long period to review)

4) Foresee dividend payout will be gradually increased for the next 10 years if the global economy & market recovery with company expansion on the perpetual growth

5) Cash pile reserve still on track (even though so much noise for bailout at different subsidiary)

6) No matter current ratio, quality of earnings ratio, NAV, cash pile position will further strengthen for upcoming season


------------------------------------------------------------------------------------------------

Beside Genting share under long term position, Keyman188 also managed to secure right company, such as :-

DLady, Ajinomoto, HLFG, HLCap, Axiata, Padini, SP Setia, IJM, Mynews, etc....

Depending how much stocks you can handle (average long term investors willing to handle 10 ~ 12 stocks, for those willing to take higher risk perhaps can handle 15 ~ 25 stocks)

Keyman188 more prefer diversification into different sectors & segmentations for more "balancing & alignment" approach on the "risk-weighted asset" management...


------------------------------------------------------------------------------------------------

Is it the right time to start your million dollar dream ???...

Is it the right time to start your long term position instead of short term profit ???....


** The final decision is on your heart now

Keyman188 always learn from professional or experts...

应买价值股还是成长股？(冷眼)

“年均复合增长率”致富关键 (冷眼)

https://klse.i3investor.com/blogs/cold_eyed_step_by_step/2021-03-20-story-h1542898574.jsp

https://www.enanyang.my/财经新闻/应买价值股还是成长股？（上）冷眼

https://klse.i3investor.com/blogs/cold_eyed_step_by_step/2021-03-21-story-h1542901613.jsp

https://www.enanyang.my/名人专栏/“年均复合增长率”致富关键（下）冷眼


------------------------------------------------------------------------------------------------

Keyman188 very gladness to share with all members here...

Keyman188 has been using 12 months period of time (since last year Mar'20) managed to organize long term portfolio position what I learned from professional (冷眼先生)

Let using Genting share as an example...

Keyman188 holding cost average about 3.30++...

Keyman188 had received dividend received for the past 12 months (based on ex-date from Apr'20 ~ Mar'21)

12/03/21 - RM 0.085

10/09/20 - RM 0.065

29/06/20 - RM 0.06

Total dividend received = RM 0.210

Dividend yield = 6.26% per share

Furthermore, since Genting part of the recovery stock with strong fundamental & growing company....

Recent share price also gradually on the recovery road...

Capital appreciation of investment also part of the investment return...

Capital appreciation growth = +65% (based on 19/03/21 closing price of RM 5.53)

Why Keyman188 so keen to keep long term position instead of short term Profit !!!........

1) Genting Management never neve stop further expansion for the business growth (even though during virus pandemic, management also taken effectiveness & efficiency measures to sustain company keep running for growth)

2) Asset quality of company no doubt definitely very strong (based the company latest balance sheet)

3) Management still able to reward dividend for all shareholders even though very struggling for the global market (still constantly payout for the past 10 years - no need talk so long period to review)

4) Foresee dividend payout will be gradually increased for the next 10 years if the global economy & market recovery with company expansion on the perpetual growth

5) Cash pile reserve still on track (even though so much noise for bailout at different subsidiary)

6) No matter current ratio, quality of earnings ratio, NAV, cash pile position will further strengthen for upcoming season


------------------------------------------------------------------------------------------------

Beside Genting share under long term position, Keyman188 also managed to secure right company, such as :-

DLady, Ajinomoto, HLFG, HLCap, Axiata, Padini, SP Setia, IJM, Mynews, etc....

Depending how much stocks you can handle (average long term investors willing to handle 10 ~ 12 stocks, for those willing to take higher risk perhaps can handle 15 ~ 25 stocks)

Keyman188 more prefer diversification into different sectors & segmentations for more "balancing & alignment" approach on the "risk-weighted asset" management...


------------------------------------------------------------------------------------------------

Is it the right time to start your million dollar dream ???...

Is it the right time to start your long term position instead of short term profit ???....


** The final decision is on your heart now